Aurora Cannabis Ships Medical Cannabis to New Zealand

Ticker: ACB · Form: 6-K · Filed: 2024-05-14T00:00:00.000Z

Sentiment: bullish

Topics: international-expansion, medical-cannabis, new-market

Related Tickers: ACB

TL;DR

Aurora Cannabis just shipped medical weed to New Zealand, opening a new market.

AI Summary

Aurora Cannabis Inc. announced on May 8, 2024, that it has made its first shipment of medical cannabis products to the New Zealand market. This marks a significant expansion for the company into a new international territory, following regulatory approvals.

Why It Matters

This shipment represents Aurora Cannabis's entry into a new international market, potentially opening up new revenue streams and increasing global reach for its medical cannabis products.

Risk Assessment

Risk Level: medium — Expansion into new international markets carries inherent risks related to regulatory compliance, market acceptance, and logistical challenges.

Key Players & Entities

FAQ

What specific medical cannabis products were included in the first shipment to New Zealand?

The filing does not specify the exact medical cannabis products included in the first shipment to New Zealand.

What are the regulatory requirements for importing medical cannabis into New Zealand?

The filing mentions regulatory approvals were obtained but does not detail the specific regulatory requirements for New Zealand.

What is Aurora Cannabis's strategy for the New Zealand market?

The filing indicates the first shipment as a market entry, but does not elaborate on a broader market strategy for New Zealand.

When did Aurora Cannabis receive approval to ship medical cannabis to New Zealand?

The filing does not provide the date when Aurora Cannabis received approval to ship medical cannabis to New Zealand, only that the first shipment occurred on or around May 8, 2024.

Are there any distribution partners mentioned for the New Zealand market?

The filing does not mention any specific distribution partners for the New Zealand market.

From the Filing

0001279569-24-000610.txt : 20240514 0001279569-24-000610.hdr.sgml : 20240514 20240514165130 ACCESSION NUMBER: 0001279569-24-000610 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20240508 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 24945358 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 3498 63 Avenue, Leduc, Alberta, Canada T9E 0G8 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News Release dated May 8, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: May 8, 2024 EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 8, 2024 Exhibit 99.1 Aurora Marks First Shipment of Medical Cannabis to the New Zealand Market NASDAQ | TSX: ACB Canada's Leading Medical Cannabis Company Launches Premium Products Redefining Patient Care EDMONTON, AB, May 8, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) the Canadian based leading global medical cannabis company, is proud to announce the arrival of Aurora branded medical cannabis products to the New Zealand market. This new line of premium dried flowers represents a significant milestone in medical cannabis accessibility in New Zealand, an emerging market poised for growth. Equiposa (CNW Group/Aurora Cannabis Inc.) The initial product portfolio includes cultivars grown exclusively by Aurora, with each strain meticulously bred and cultivated to address a variety of patient needs. These carefully crafted offerings reflect Aurora's commitment to providing prescribers and patients with unparalleled quality, potency , and therapeutic benefits. "As a global leader in medical cannabis, Aurora is proud to be at the forefront of advancing patient access in New Zealand with this first and meaningful product launch," said Miguel Martin, CEO, Aurora. "We are thrilled to offer prescribers and patients premium dried flower options that embody our dedication to opening the world to cannabis while prioritizing patient care and well-being. We see great potential in the New Zealand market and intend to leverage symmetry with our leadership in Australia." Equiposa, the first balanced dried cannabis product in the market, is a testament to Aurora's commitment to providing diverse options to meet patient needs. This inaugural product offering from Aurora sets a new standard for medical cannabis in New Zealand, backed by uncompromised quality and scientific rigour. Aurora strives to make a meaningful difference in the lives of patients across New Zealand, empowering them to manage their health and wellness with confidence. About Aurora Cannabis Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Austral

View on Read The Filing